Plenary Programme

Monday 27 May

METABOLIC DYSFUNCTION IN CARDIOVASCULAR DISEASE

Macrophage immunometabolism: opportunities for phenotypical modulation?
Luke A. O’Neill, Dublin, Ireland
Lipids, Lipases and Fatty Liver Disease
Helen Hobbs, Dallas, USA
Exploring the complexity in transcriptional regulation of energy homeostatis
To be announced
New partners in cholesterol signalling/metabolism
To be announced

Tuesday 28 May

PREVENTING CVD RISK: WHERE DO WE STAND?

Biomarkers predicting CVD
Chris Packard, Glasgow, UK
The genetic burden in CVD
Heribert Schunkert, München, Germany
Estimating risk: What's new?
Ian Graham, Dublin, Ireland
Lale Tokgözoglu, Ankara, Turkey
Thomas Lüscher, Zurich, Switzerland
Kausik Ray, London, UK

Wednesday 29 May

LOOKING TO THE FUTURE - NOVEL TREATMENT STRATEGIES

The immune system: The next game-changer?
Matthias Nahrendorf, Boston, USA
System-level analyses of inflammatory and repair macrophages reveal an integrated circuitry of lipid and epigenomic changes
Laszlo Nagy, Debrecen, Hungary
New lipid drugs: Is LDL done, ready for new targets?
Marc Sabatine, Boston, USA
Functional food: Is there a future?
To be announced